Patents by Inventor Abbas Walji

Abbas Walji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11066396
    Abstract: The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: July 20, 2021
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Abbas Walji, Richard Berger, Craig A. Stump, Kelly-Ann S. Schlegel, James J. Mulhearn, Thomas J. Greshock, Deping Wang, Mark E. Fraley, Kristen G. Jones
  • Publication number: 20210069288
    Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Application
    Filed: August 28, 2020
    Publication date: March 11, 2021
    Inventors: Hubert Josien, Abbas Walji, Harold B. Wood, Fa-Xiang Ding, Jian Liu, Thomas Joseph Tucker, Michael Man-Chu Lo, Liangqin Guo
  • Publication number: 20190185462
    Abstract: The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
    Type: Application
    Filed: June 19, 2017
    Publication date: June 20, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abbas Walji, Richard Berger, Craig A. Stump, Kelly Ann S. Schlegel, James J. Mulhearn, Thomas J. Greshock, Deping Wang, Mark E. Fraley, Kristen G. Jones
  • Patent number: 10150780
    Abstract: The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 11, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas H. Graham, Mark W. Embrey, Abbas Walji, Sherman T. Waddell
  • Patent number: 9951079
    Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: April 24, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark W. Embrey, Kerim Babaoglu, Abbas Walji, John S. Wai, Paul J. Coleman
  • Publication number: 20170362252
    Abstract: The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: December 4, 2015
    Publication date: December 21, 2017
    Inventors: Thomas H. Graham, Mark W. Embrey, Abbas Walji, Sherman T. Waddell
  • Publication number: 20170305923
    Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: June 9, 2014
    Publication date: October 26, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Mark W. Embrey, John M. Sanders, Kerim Babaoglu, Abbas Walji, John S. Wai, Paul J. Coleman
  • Patent number: 9714243
    Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: July 25, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark W. Embrey, Thomas H. Graham, Abbas Walji, Sherman T. Waddell, Tao Yu, Yonglian Zhang, Wensheng Liu, Paul J. Coleman, John Wai, Thomas Steele, Christina Di Marco
  • Publication number: 20150329539
    Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 19, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark W. Embrey, Thomas H. Graham, Abbas Walji, Sherman T. Waddell, Tao Yu, Yonglian Zhang, Wensheng Liu, Paul J. Coleman, John Wai, Thomas Steele, Christina Di Marco